Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca to acquire Alexion for $39bn

Deal will bolster AZ's portfolio with rare disease assets

AstraZeneca (AZ) has paid a jaw-dropping $39bn to acquire Alexion in a bid to bolster and diversify its own drug portfolio with rare disease assets.

Alexion shareholders are set to receive $60 in cash for each share and a total consideration of $39bn or $175 per share.

The acquisition is one of the largest deals announced this year and is also AZ’s largest corporate acquisition ever, according to Reuters.

The deal means AZ will immediately gain assets within Alexion’s commercial portfolio, estimated to be worth around $6bn. This includes the company’s complement component 5 (C5) inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), which are already available in the US and EU.

On top of Alexion’s commercial products, AZ will also gain a portfolio of assets currently in clinical development, consisting of a pipeline of 11 molecules across over 20 clinical-development programmes.

AZ hopes to combine its own precision medicine expertise with Alexion’s specialist rare disease knowledge to leverage its capabilities in a number of therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.

"Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology,” said Pascal Soriot, chief executive officer, AZ.

“We look forward to welcoming our new colleagues at Alexion so that together we can build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients,” he added.

While the boards of directors of both companies have unanimously approved the acquisition, it is still subject to regulatory clearances and approval of both Alexion and AZ shareholders.

If all goes to plan, the companies expect the acquisition to close in the third quarter of 2021, with Alexion shareholders set to own 15% of the combined company upon completion.

AZ is also projecting that the acquisition will deliver double-digit average annual revenue growth until 2025, most likely driven by Soliris, which is currently Alexion’s main source of sales.

Rare disease is increasingly becoming an area of focus for big pharma, with the Alexion acquisition marking AZ’s first major foray into this sector.

By EvaluatePharma’s forecasts, the global rare disease market is set to grow by a low double digit percentage until 2026.

“For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. I am incredibly proud of what our organisation has accomplished and am grateful to our employees for their contributions,” said Ludwig Hantson, chief executive officer of Alexion.

“This transaction marks the start of an exciting new chapter for Alexion. We bring to AstraZeneca a strong portfolio, an innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics,” he added.

Article by
Lucy Parsons

16th December 2020

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...